Study of Diazepam Buccal Film Administered in the Interictal and in the Ictal-Periictal States to Adults With Epilepsy

A Multicenter, Open Label, Crossover Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03179891

Enrollment

Registered

2017-06-07

Start date

2017-05-25

Completion date

2018-12-21

Last updated

2020-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Keywords

Interictal, Ictal/peri-ictal

Brief summary

This Phase 2 open-label, two-way study was conducted in adult subjects with epilepsy who were on stable regimens of anti-epileptic drugs (AEDs) and who were admitted to an Epilepsy Monitoring Unit (EMU), General Clinical Research Center (GCRC), or similar facility for evaluation of their seizures. All subjects received a single DBF 12.5 mg dose during the Interictal State and a single DBF 12.5 mg dose during the Ictal/peri-ictal state with at least 14 days washout between the 2 doses.

Detailed description

This was a Phase 2 multicenter, open-label, two-way study conducted in adult subjects to assess the bioavailability, pharmacokinetics, and safety of DBF during the Interictal Period and during the Ictal/peri-ictal Period, with a minimum of 14 days of washout between periods. Subjects had a clinical diagnosis of epilepsy (with generalized tonic-clonic seizures or focal seizures with impaired awareness) who were on stable regimens of anti-epileptic drugs and were scheduled for admission to an EMU, GCRC, or similar facility for evaluation. All subjects were to receive a single 12.5-mg dose of study drug, without regard to meals, during both Interictal Period and Ictal/peri-ictal Period. The treatment was identical for both periods. Treatment sequence was not randomized. The interictal period and ictal/peri-ictal could occur in either order as determined by seizure occurrence. Interictal Period: Subjects were considered to be in an interictal state if an interval of at least 3 hours had elapsed since any clinically observable postictal signs or symptoms (from the last observed seizure) and the subject had been seizure-free over this period. Subjects on electroencephalogram (EEG) video monitoring were to be considered to be in an interictal state if an interval of at least 3 hours had elapsed since there were any postictal electrical findings on EEG. Ictal/peri-ictal Period: For the purposes of this study, the ictal state was defined as an ongoing clinically observable seizure or seizure activity as verified via EEG. The periictal state was defined clinically as the subject's immediate postictal state following a generalized tonic-clonic (GTC) seizure or focal seizure with impaired awareness, and within 5 minutes following the last clonic jerk. For subjects on EEG video monitoring, the periictal state was to be defined as less than 5 minutes after cessation of seizure activity as verified via EEG.

Interventions

DRUGDiazepam Buccal Film 12.5 mg

All subjects received a single dose of DBF 12.5 mg during the interictal state and during the ictal/peri-ictal state with at least 14 days washout between the 2 treatment periods

Study design

Allocation

NON_RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

This was a multicenter, open-label study comprised of 2 treatment periods with a minimum 14 days washout between the 2 treatment periods.

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

Potential subjects meeting all of the following criteria may be included in the study: 1. Subjects scheduled for admission to the institution's EMU, GCRC (General Clinical Research Center) or similar facility for evaluation within 28 days. 2. Male and female subjects between 18 to 65 years of age, inclusive. 3. Subjects having a body weight of ≥ 40 kg to 111 kg. 4. Subjects have a clinical diagnosis of epilepsy and are scheduled to be admitted to an Epilepsy Monitoring Unit (EMU) for extracranial video-Electroencephalogram (EEG) recording of a seizure event for evaluation of their epilepsy. 5. Subjects have an average frequency of \> 1 seizure every 3 days or \> 10 seizures / month as documented by seizure diaries dispensed at the Screening Visit and verified prior to initiation of Period A or Period B. 6. Female subjects have a negative serum pregnancy test at Screening. Female subjects of childbearing potential (i.e., not surgically sterile or 2 years postmenopausal) must have a negative pregnancy test at screening and a partner who is sterile, agree to abstinence, be practicing double barrier contraception or using an FDA approved contraceptive (e.g., licensed hormonal or barrier methods) for greater than 2 months prior to screening visit and commit to an acceptable form of birth control for the duration of the study and for 30 days after participation in the study. 7. Subjects are currently receiving at least one antiepileptic medication. 8. Subjects or subject's legally authorized representative (LAR) must be willing and able to complete informed consent/assent and HIPAA authorization. 9. Subjects must agree and must be willing to comply with all required study procedures while in the EMU or GCRC. 10. Ability to comprehend and be informed of the nature of the study, as assessed by the PI or Sub-Investigator. 11. Ability to consume standard meals. 12. Availability to volunteer for the entire study duration and willing to adhere to all protocol requirements.

Exclusion criteria

Potential subjects meeting any of the following criteria will be excluded: 1. Subjects having a progressive neurological disorder such as brain tumor, demyelinating disease, or degenerative central nervous system (CNS) disease that is likely to progress in the next 12 months. 2. Subjects having respiratory failure (or is at risk for respiratory failure) or other severe cardiorespiratory disease with New York Heart Association Class III or IV functional status, or requires supplemental oxygen. 3. Female subjects who are lactating or positive serum pregnancy test (ß-hCG) at screening for female subjects ≥12 years of age. 4. Subjects with severe psychiatric disease that in the Investigator's judgment would prevent the patient's successful completion of the study. 5. Subjects who have an episode of status epilepticus, as determined by the Principal Investigator/Sub-Investigator, at any time during Period B (EMU, GCRC or similar facility Visit 6. Subjects with known history or presence of any clinically significant hepatic (e.g. hepatic impairment), renal/genitourinary (renal impairment, kidney stones), psychiatric, dermatological or hematological disease or condition unless determined as not clinically significant by the Principal Investigator/Sub-Investigator and confirmed by Sponsor via written communication prior to subject enrollment. 7. Subjects with any clinically significant illness other than epilepsy within 30 days prior to first dosing, as determined by the Principal Investigator/Sub-Investigator. 8. Subjects with any significant physical or organ abnormality as determined by the Principal Investigator/Sub-Investigator. 9. Subjects with any significant lesion of the oral cavity or having oral prophylactic procedures within 30 days prior to first dosing. 10. Subjects with a QTc interval QTcF\>450 msec for males and QTcF\>470 msec for females on screening ECG, unless determined as not clinically significant by the Investigator. 11. Subjects with a positive test result for any of the following: drugs of abuse (amphetamines, cocaine, opiates, or phencyclidine), a positive breath alcohol test. 12. Subjects with a known history or presence of: a. Alcohol abuse or dependence within one year prior to first drug administration; b. Drug abuse or dependence; c. Hypersensitivity or idiosyncratic reaction to diazepam, its excipients, sodium phosphates; and/or related substances, e.g. benzodiazepines; d. Glaucoma (open or acute narrow angle); e. Severe allergic reactions (e.g. anaphylactic reactions, angioedema 13. Subjects who have participated in another clinical trial or who received an investigational drug within 30 days prior to first drug administration or 5 half-lives of the investigational drug-whichever is the longer period. 14. Blood or plasma donation within 30 days prior to Screening 15. Subjects not willing or unable to tolerate blood draws. 16. Subjects who have received any other dosage form of diazepam or benzodiazepines within 2 weeks prior to entering Period A or Period B. 17. Consumption of alcohol within 48 hours before dosing and food or beverages containing grapefruit, star fruit, Seville oranges, and/or pomelo or their derived products (e.g., fruit juice) within 10 days prior to first drug administration. 18. Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (e.g. cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem, or HIV antivirals) and strong inducers of CYP enzymes (e.g. glucocorticoids, St. John´s Wort, or rifampicin) in the previous 30 days before first drug administration \[barbiturates, carbamazepine, and phenytoin are allowed since these are common AEDs (Anti-epileptic drugs)\]. 19. Use of any monoamine oxidase (MAO) inhibitors (e.g. phenelzine, tranylcypromine), phenothiazines (chlorpromazine) within 30 days prior to first drug administration. 20. Employee or immediate relative of an employee of the investigator, MonoSol Rx LLC, any of its affiliates or partners, or inVentiv Health.

Design outcomes

Primary

Measure	Time frame	Description
Tmax Pharmacokinetic EndPoints	-2 to 0, 0.25, 0.5, 1, 2, 4, 8, 24, 48, 96, 144, 192, 240 hours	Observed time to reach maximum drug concentration (Tmax)
Cmax Pharmacokinetic EndPoints	-2 to 0, 0.25, 0.5, 1, 2, 4, 8, 24, 48, 96, 144, 192, 240 hours	Observed Peak Drug Concentration (Cmax)
Area Under the Plasma Concentration Curve Pharmacokinetic EndPoints	-2 to 0, 0.25, 0.5, 1, 2, 4, 8, 24, 48, 96, 144, 192, 240 hours	Area under the Plasma Concentration -time curve from time zero until the last measured time (AUC0-t)

Secondary

Measure	Time frame	Description
Usability Endpoint: Exit of Saliva During the Time the Diazepam Buccal Film (DBF) Was Adhered to Buccal Mucosa	Subject was observed for 15 minutes immediately following DBF placement/adhesion	The observer documented if any saliva was seen to exit the mouth during the time the DBF was adhered to buccal mucosa
Usability Endpoint - Successful Insertion/Placement of the Diazepam Buccal Film (DBF) on First Attempt	Subject was observed for 15 minutes after initial film placement/adhesion	Number of subjects with unsuccessful insertion/placement of the DBF on first attempt at administration Number of subjects with successful insertion/placement of the DBF on first attempt at administration Placement is judged to be successful when film adheres to the center of buccal mucosa of either right or left cheek. Unsuccessful placements were followed by a subsequent successful insertion/placement of DBF
Usability Endpoint: Amount of Saliva That Exited the Mouth After Film Placement	Subject was observed for 15 minutes immediately following DBF placement/adhesion	If Yes - saliva exited the mouth during the time, estimate in milliliters of the amount of saliva that exited the mouth after DBF placement on the buccal surface
Usability Endpoint: Swallowing the Film Before Complete Disintegration/Dissolution	Subject was observed for 15 minutes immediately following DBF placement/adhesion	Was the film noted to have been swallowed by the subject ? Yes No Subjects were instructed to swallow any remnants of film still present in oral cavity 15 minutes after initial film placement. Results include subjects who swallowed film at any point during the 15 minutes immediately after initial film placement.
Usability Endpoint: Retention of Diazepam Buccal Film (DBF) From Placement to Complete Disintegration	Subject was observed for 15 minutes immediately following DBF placement/adhesion	Was the DBF spit out or blown out by the subject after placement on buccal mucosa or did the subject chew, talk, or move the DBF prior to complete disintegration/dissolution? Yes No

Countries

United States

Participant flow

Recruitment details

Planned enrollment was 40 adult male and female subjects with a clinical diagnosis of epilepsy requiring admission to an epilepsy monitoring unit, a general clinical research center, or similar facility for evaluation of seizures. A minimum of 30 subjects was expected to complete the study.

Pre-assignment details

A total of 35 subjects were enrolled to receive a 12.5-mg dose of study drug during both the interictal and the ictal/peri-ictal period which occurred in either order as determined by seizure occurrence.

Participants by arm

Arm	Count
Adult Subjects With Epilepsy Adult subjects with epilepsy admitted to an Epilepsy Monitoring Unit to receive a single 12.5 mg DBF dose during the Ictal Phase and during the Interictal/Peri-ictal Phase with at least 14 days between the 2 periods	35
Total	35

Withdrawals & dropouts

Period	Reason	FG000	FG001
First Intervention	Protocol Violation	0	1
First Intervention	Unspecified reason	1	0
First Intervention	Withdrawal by Subject	1	1

Baseline characteristics

Characteristic	Adult Subjects With Epilepsy
Age, Categorical <=18 years	0 Participants
Age, Categorical >=65 years	6 Participants
Age, Categorical Between 18 and 65 years	29 Participants
BMI	27.84 kg/m^2 STANDARD_DEVIATION 7.01
Ethnicity (NIH/OMB) Hispanic or Latino	9 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	26 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants
Height	165.64 cm STANDARD_DEVIATION 10.81
Race (NIH/OMB) American Indian or Alaska Native	2 Participants
Race (NIH/OMB) Asian	1 Participants
Race (NIH/OMB) Black or African American	5 Participants
Race (NIH/OMB) More than one race	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	6 Participants
Race (NIH/OMB) Unknown or Not Reported	2 Participants
Race (NIH/OMB) White	19 Participants
Region of Enrollment United States	35 participants
Sex: Female, Male Female	18 Participants
Sex: Female, Male Male	17 Participants
Weight	79.24 kg STANDARD_DEVIATION 19.58

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	0 / 33	0 / 33
other Total, other adverse events	12 / 33	14 / 33
serious Total, serious adverse events	0 / 33	1 / 33

Outcome results

Primary

Area Under the Plasma Concentration Curve Pharmacokinetic EndPoints

Area under the Plasma Concentration -time curve from time zero until the last measured time (AUC0-t)

Time frame: -2 to 0, 0.25, 0.5, 1, 2, 4, 8, 24, 48, 96, 144, 192, 240 hours

Population: The pharmacokinetic analysis set comprised only those subjects who contributed a valid pharmacokinetic profile for the given analysis and whose predose concentration of the relevant analyte did not exceed 5% of the subsequent Cmax.

Arm	Measure	Value (MEAN)	Dispersion
Interictal State	Area Under the Plasma Concentration Curve Pharmacokinetic EndPoints	560.18 h*ng/mL	Standard Deviation 219.7
Ictal/Peri-ictal State	Area Under the Plasma Concentration Curve Pharmacokinetic EndPoints	498.78 h*ng/mL	Standard Deviation 319.09

Primary

Cmax Pharmacokinetic EndPoints

Observed Peak Drug Concentration (Cmax)

Time frame: -2 to 0, 0.25, 0.5, 1, 2, 4, 8, 24, 48, 96, 144, 192, 240 hours

Arm	Measure	Value (MEAN)	Dispersion
Interictal State	Cmax Pharmacokinetic EndPoints	230.32 ng/mL	Standard Deviation 89
Ictal/Peri-ictal State	Cmax Pharmacokinetic EndPoints	209.49 ng/mL	Standard Deviation 120.18

Primary

Tmax Pharmacokinetic EndPoints

Observed time to reach maximum drug concentration (Tmax)

Time frame: -2 to 0, 0.25, 0.5, 1, 2, 4, 8, 24, 48, 96, 144, 192, 240 hours

Arm	Measure	Value (MEDIAN)
Interictal State	Tmax Pharmacokinetic EndPoints	1.000 hours
Ictal/Peri-ictal State	Tmax Pharmacokinetic EndPoints	0.525 hours

Secondary

Usability Endpoint: Amount of Saliva That Exited the Mouth After Film Placement

If Yes - saliva exited the mouth during the time, estimate in milliliters of the amount of saliva that exited the mouth after DBF placement on the buccal surface

Time frame: Subject was observed for 15 minutes immediately following DBF placement/adhesion